Madeleine covers PCR, nucleic acid amplification, and sample prep technologies for GenomeWeb.
The firm, which started in immunodiagnostics, is constructing a new building to house its molecular biology business.
The approach is based on a new approval of the BacT/ALERT Virtuo system and new indications for the firm's procalcitonin assay.
The test was made about 10 times more sensitive than standard rapid immunoassays by tweaking a number of the firm's proprietary technologies, a company official said.
The firm's SteriPath device can reduce contamination tenfold, and it has hired a new chief commercialization officer to expand its reach in the preanalytical diagnostics space.
The test was approved for lab use, but it runs on a platform with the potential for point-of-care applications.
The Dutch firm expects its product to be the first commercial test on the market to diagnose IBD by analyzing a patient's gut microbiome.
The Bay Area firm is planning to launch a low-cost, microfluidics-based infectious disease diagnostic called the Simple Chip in the next few years.
The method uses graphene-coated silica particles fused to complementary RNA to register impedance changes in the presence of viruses.
The company has also developed software that will enable automated melt curve analysis on Cepheid's existing GeneXpert platforms.
A handful of devices are pioneering less painful, more efficient methods to collect blood for testing.